Last reviewed 2026-04-23 · How we verify

Long GnRH agonist + HRT

A combination therapy that suppresses gonadotropin-releasing hormone (GnRH) signaling to reduce sex hormone production, followed by hormone replacement therapy (HRT) to manage menopausal symptoms.

A combination therapy that suppresses gonadotropin-releasing hormone (GnRH) signaling to reduce sex hormone production, followed by hormone replacement therapy (HRT) to manage menopausal symptoms. Used for Endometriosis with menopausal symptom management, Uterine fibroids (leiomyomas) with hormone replacement.

At a glance

Mechanism of action

Long-acting GnRH agonists desensitize the pituitary gland, leading to sustained suppression of luteinizing hormone (LH) and follicle-stimulating hormone (FSH), which dramatically reduces estrogen and progesterone levels. The subsequent HRT component replaces these hormones in a controlled manner to alleviate vasomotor and other menopausal symptoms while maintaining the therapeutic benefits of hormone suppression. This approach is typically used in conditions where estrogen suppression is beneficial (such as endometriosis or certain gynecological conditions) while mitigating the adverse effects of hypoestrogenism.

Approved indications

• Endometriosis with menopausal symptom management
• Uterine fibroids (leiomyomas) with hormone replacement

Common side effects

• Hot flashes
• Night sweats
• Vaginal dryness
• Headache
• Mood changes
• Injection site reactions

Key clinical trials

• GnRH Agonist Plus Hormone Replacement Therapy vs Hormone Replacement Therapy on IVF Outcomes (PHASE3)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.